Evidence map›Paper›PMID 34131116›Full record

ArticleNature communications2021

Molecular benchmarks of a SARS-CoV-2 epidemic.

Hakon Jonsson, Olafur T Magnusson, Pall Melsted, Jonas Berglund, Arna B Agustsdottir, Berglind Eiríksdottir, Run Fridriksdottir, Elisabet Eir Garðarsdottir, Gudmundur Georgsson, Olafia S Gretarsdottir and 37 more

Abstract read
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

47 authors.

Hakon JonssondeCODE genetics/Amgen, Inc., Reykjavik, Iceland.ORCID 0000-0001-6197-494X
Olafur T MagnussondeCODE genetics/Amgen, Inc., Reykjavik, Iceland.
Pall MelsteddeCODE genetics/Amgen, Inc., Reykjavik, Iceland.
Jonas BerglunddeCODE genetics/Amgen, Inc., Reykjavik, Iceland.
Arna B AgustsdottirdeCODE genetics/Amgen, Inc., Reykjavik, Iceland.
Berglind EiríksdottirdeCODE genetics/Amgen, Inc., Reykjavik, Iceland.
Run FridriksdottirdeCODE genetics/Amgen, Inc., Reykjavik, Iceland.
Elisabet Eir GarðarsdottirdeCODE genetics/Amgen, Inc., Reykjavik, Iceland.
Gudmundur GeorgssondeCODE genetics/Amgen, Inc., Reykjavik, Iceland.
Olafia S GretarsdottirLandspitali University Hospital, Reykjavik, Iceland.
Kjartan R GuðmundssondeCODE genetics/Amgen, Inc., Reykjavik, Iceland.
Thora Rosa GunnarsdottirLandspitali University Hospital, Reykjavik, Iceland.
Hannes EggertssondeCODE genetics/Amgen, Inc., Reykjavik, Iceland.ORCID 0000-0002-1674-9978
Arnaldur GylfasondeCODE genetics/Amgen, Inc., Reykjavik, Iceland.
Hilma HolmdeCODE genetics/Amgen, Inc., Reykjavik, Iceland.ORCID 0000-0002-9517-6636
Brynjar O JenssondeCODE genetics/Amgen, Inc., Reykjavik, Iceland.
Aslaug JonasdottirdeCODE genetics/Amgen, Inc., Reykjavik, Iceland.
Frosti JonssondeCODE genetics/Amgen, Inc., Reykjavik, Iceland.
Kamilla S JosefsdottirDirectorate of health, Reykjavik, Iceland.
Marianna ThordardottirDirectorate of health, Reykjavik, Iceland.
Karl G KristinssonLandspitali University Hospital, Reykjavik, Iceland.
Þórður KristjánssondeCODE genetics/Amgen, Inc., Reykjavik, Iceland.
Droplaug N MagnusdottirdeCODE genetics/Amgen, Inc., Reykjavik, Iceland.
Louise le RouxdeCODE genetics/Amgen, Inc., Reykjavik, Iceland.ORCID 0000-0002-9491-9653
Jona SaemundsdottirdeCODE genetics/Amgen, Inc., Reykjavik, Iceland.
Asgeir SigurdssondeCODE genetics/Amgen, Inc., Reykjavik, Iceland.
Gudrun SigmundsdottirDirectorate of health, Reykjavik, Iceland.
Gardar SveinbjornssondeCODE genetics/Amgen, Inc., Reykjavik, Iceland.
Solvi RognvaldssondeCODE genetics/Amgen, Inc., Reykjavik, Iceland.
Ogmundur EirikssondeCODE genetics/Amgen, Inc., Reykjavik, Iceland.ORCID 0000-0003-0139-5107
Magnus Karl MagnussondeCODE genetics/Amgen, Inc., Reykjavik, Iceland.ORCID 0000-0001-8593-4934
Kristin Eva SveinsdottirdeCODE genetics/Amgen, Inc., Reykjavik, Iceland.
Maney SveinsdottirLandspitali University Hospital, Reykjavik, Iceland.
Emil Aron ThorarensendeCODE genetics/Amgen, Inc., Reykjavik, Iceland.
Bjarni ThorbjornssondeCODE genetics/Amgen, Inc., Reykjavik, Iceland.
Arthur LöveLandspitali University Hospital, Reykjavik, Iceland.
Gudmundur L NorddahldeCODE genetics/Amgen, Inc., Reykjavik, Iceland.
Ingileif JonsdottirdeCODE genetics/Amgen, Inc., Reykjavik, Iceland.ORCID 0000-0001-8339-150X
Patrick SulemdeCODE genetics/Amgen, Inc., Reykjavik, Iceland.ORCID 0000-0001-7123-6123
Gisli MassondeCODE genetics/Amgen, Inc., Reykjavik, Iceland.
Alma MollerDirectorate of health, Reykjavik, Iceland.
Thorolfur GudnasonDirectorate of health, Reykjavik, Iceland.
Mar KristjanssonLandspitali University Hospital, Reykjavik, Iceland.
Agnar HelgasondeCODE genetics/Amgen, Inc., Reykjavik, Iceland.
Daniel F GudbjartssondeCODE genetics/Amgen, Inc., Reykjavik, Iceland.ORCID 0000-0002-5222-9857
Unnur ThorsteinsdottirdeCODE genetics/Amgen, Inc., Reykjavik, Iceland.
Kari StefanssondeCODE genetics/Amgen, Inc., Reykjavik, Iceland. kstefans@decode.is.ORCID 0000-0003-1676-864X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A pressing concern in the SARS-CoV-2 epidemic and other viral outbreaks, is the extent to which the containment measures are halting the viral spread. A straightforward way to assess this is to tally the active cases and the recovered ones throughout the epidemic. Here, we show how epidemic control can be assessed with molecular information during a well characterized epidemic in Iceland. We demonstrate how the viral concentration decreased in those newly diagnosed as the epidemic transitioned from exponential growth phase to containment phase. The viral concentration in the cases identified in population screening decreased faster than in those symptomatic and considered at high risk and that were targeted by the healthcare system. The viral concentration persists in recovering individuals as we found that half of the cases are still positive after two weeks. We demonstrate that accumulation of mutations in SARS-CoV-2 genome can be exploited to track the rate of new viral generations throughout the different phases of the epidemic, where the accumulation of mutations decreases as the transmission rate decreases in the containment phase. Overall, the molecular signatures of SARS-CoV-2 infections contain valuable epidemiological information that can be used to assess the effectiveness of containment measures.

Indexed as

EpidemicsAnimalsBenchmarkingCOVID-19HumansIcelandMolecular EpidemiologyMutationRNA, ViralSARS-CoV-2RNA, Viral

Identifiers

PMID34131116
PMCPMC8206085

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.